On the public citation graph

Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study

https://doi.org/10.1007/s00277-022-04764-4

0 signed · 22 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2020.4600openalex-snapshot

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

inferredcites →https://doi.org/10.1016/s1470-2045(13)70152-9openalex-snapshot

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

inferredcites →https://doi.org/10.1056/nejmoa0901409openalex-snapshot

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

inferredcites →https://doi.org/10.1056/nejmoa0904544openalex-snapshot

Anthracycline Dose Intensification in Acute Myeloid Leukemia

inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-3433openalex-snapshot

Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia

inferredcites →https://doi.org/10.1182/blood-2010-03-273243openalex-snapshot

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

inferredcites →https://doi.org/10.1182/blood-2011-06-361410openalex-snapshot

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

inferredcites →https://doi.org/10.1182/blood-2016-08-733196openalex-snapshot

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

inferredcites →https://doi.org/10.1182/blood.v58.6.1203.1203openalex-snapshot

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B

inferredcites →https://doi.org/10.1182/blood.v77.8.1666.1666openalex-snapshot

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

inferredcites →https://doi.org/10.1186/s12935-018-0716-7openalex-snapshot

Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients

inferredcites →https://doi.org/10.1200/jco.1992.10.7.1103openalex-snapshot

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.

inferredcites →https://doi.org/10.1200/jco.20.03736openalex-snapshot

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

inferredcites →https://doi.org/10.1200/jco.2008.20.6490openalex-snapshot

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10

inferredcites →https://doi.org/10.1200/jco.2009.23.2652openalex-snapshot

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

inferredcites →https://doi.org/10.1200/jco.2011.37.1286openalex-snapshot

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

inferredcites →https://doi.org/10.1200/jco.2012.47.4874openalex-snapshot

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

inferredcites →https://doi.org/10.1200/jco.2017.72.8618openalex-snapshot

Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4156508openalex-extracted

inferred← citeshttps://doi.org/10.1016/j.cclet.2022.107923openalex-snapshot

Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations

inferred← citeshttps://doi.org/10.1021/acssynbio.4c00043openalex-snapshot

Diverse Combinatorial Biosynthesis Strategies for C–H Functionalization of Anthracyclinones

inferred← citeshttps://doi.org/10.3389/fchem.2023.1250043openalex-snapshot

Drug repurposing based on the similarity gene expression signatures to explore for potential indications of quercetin: a case study of multiple sclerosis

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.